People

Biological E appoints V Krishnakumar as CEO of Biopharma CDMO

He will lead the development of the company’s global biopharmaceutical CDMO platform spanning vaccines, antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), recombinant proteins and mRNA therapeutics.

  • By IPP Bureau | October 03, 2026

Biological E. Limited has appointed V Krishnakumar (KK) as Chief Executive Officer – Biopharma CDMO.

He will lead the development of the company’s global biopharmaceutical CDMO platform spanning vaccines, antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), recombinant proteins and mRNA therapeutics.

Krishnakumar joins Biological E. with extensive experience across life sciences strategy, CDMO, investment banking, M&A and business transformation. He previously served as Executive Director & COO at ERIS Lifesciences and Partner, Lifesciences Investment Banking at EY.

Earlier, he was Executive Director, Lifesciences Investment Banking at Avendus Capital and President – Strategy at Piramal Pharma Solutions. He began his career with McKinsey & Company as an Engagement Manager.

His appointment comes as Biological E. seeks to expand its global biopharmaceutical CDMO capabilities and strengthen its presence across emerging and advanced therapeutic platforms.

 

 

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.